Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 82

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 82
---
      Expired(676,528)52.13  Outstanding at September 30, 20256,451,403 40.68 Restricted Stock Units Number of Restricted Stock Units Weighted Average Grant Date Fair Value (Per Share)Unvested at December 31, 20242,769,728 $32.07      Granted2,449,865 26.00      Vested(766,373)36.67      Forfeited(239,411)28.45 Unvested at September 30, 20254,213,809 27.82 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  27

The weighted average fair value of stock options granted during the nine months ended September 30, 2025 was $13.73 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:Black-Scholes Weighted Average AssumptionNine Months Ended September 30, 2025Expected dividend yieldNoneRisk-free interest rate4.14%Expected volatility57.9%Expected term of options5.14 yearsEmployee Stock Purchase PlanThe Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the nine months ended September 30, 2025, 100,728 shares were purchased and issued through the ESPP.

NOTE 13—NET INCOME (LOSS) PER COMMON SHARE

Basic and diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is calculated by dividing the net income (loss) attributable to common shares by the weighted average number of common shares outstanding plus dilutive potential common shares outstanding during the period.Potential common shares include the shares of common stock issuable upon the exercise of outstanding stock options, the vesting of RSUs and the purchase of